Virpax has announced an expansion of its license agreement with Nanomerics to add worldwide rights to AnQlar nasal spray, an antiviral mucoadhesive polymer derived from chitosan. The original license agreement, which was announced in August 2020, included North American rights only. According to Nanomerics, the additional funds paid by Virpax for the expanded license … [Read more...] about Virpax gets worldwide rights to Nanomerics’ AnQlar antiviral nasal spray
News
DFE Pharma, Sterling, and Harro Höfliger partner as “INTO” to offer DPI development services
Inhaled lactose manufacturer DFE Pharma, API manufacturer Sterling, and filling/packaging company Harro Höfliger have partnered to create an early development service for DPIs called "INTO" (Inhalation Together). According to the INTO web site, the partnership will offer API development and characterization services, pre-formulation and formulation studies, and … [Read more...] about DFE Pharma, Sterling, and Harro Höfliger partner as “INTO” to offer DPI development services
Intranasal pro-resolving lipid mediators improve cognitive function in mouse model of Alzheimer’s Disease
Researchers from the Karolinska Institutet and Louisiana State University (LSU) Health New Orleans have published an article describing positive effects of intranasal delivery of a cocktail of five different pro-resolving lipid mediators in a mouse model of Alzheimer’s Disease, including improvements in cognitive function. The article, titled "Intranasal delivery of … [Read more...] about Intranasal pro-resolving lipid mediators improve cognitive function in mouse model of Alzheimer’s Disease
Impel Neuropharma secures $100 million for continued commercialization of Trudhesa nasal spray
Funds managed by Oaktree Capital Management will provide $100 million in funding to Impel NeuroPharma, with $50 million of that amount in cash up front as part of a royalty agreement on net sales of Trudhesa dihydroergotamine (DHE) nasal spray and the other $50 million in the form of a credit facility. The FDA approved Trudhesa for the treatment of migraine in … [Read more...] about Impel Neuropharma secures $100 million for continued commercialization of Trudhesa nasal spray
Ji Xing gets go-ahead for Phase 3 trial of OC-01 varenicline nasal spray for dry eye disease in China
According to Ji Xing Pharmaceuticals, Chinese regulators have approved the company's application for a Phase 3 clinical trial of OC-01 varenicline nasal spray for the treatment of dry eye disease in China. Ji Xing acquired the Chinese rights to OC-01 and OC-02 simpinicline nasal spray for the treatment of dry eye disease from Oyster Point Pharma in August 2021. In the … [Read more...] about Ji Xing gets go-ahead for Phase 3 trial of OC-01 varenicline nasal spray for dry eye disease in China
Consortium partners with RocketVax on intranasal COVID-19 vaccine development
A Swiss-German consortium led by Volker Thiel of the Institute of Virology and Immunology and the University of Bern has partnered with Swiss startup RocketVax to develop two live attenuated intranasal vaccine candidates against SARS-CoV-2 for planned Phase 1 trials. The consortium, which also includes researchers from the University of Geneva, the Freie Universität … [Read more...] about Consortium partners with RocketVax on intranasal COVID-19 vaccine development
Positive Phase 1b results for Pulmatrix’s PUR1800 inhaled narrow spectrum kinase inhibitor
Pulmatrix has announced that topline data from a Phase 1b study of its PUR1800 dry powder narrow spectrum kinase inhibitor in COPD patients showed that inhaled PUR1800 produced "low and consistent systemic exposure" with "no observed safety signals" In January 2020, when Pulmatrix announced a license agreement with the Lung Cancer Initiative at Johnson & Johnson … [Read more...] about Positive Phase 1b results for Pulmatrix’s PUR1800 inhaled narrow spectrum kinase inhibitor
FDA approves Rx-to-OTC switch for Perrigo’s Nasonex 24HR Allergy nasal spray
According to Perrigo, the FDA has approved its NDA for Nasonex 24HR Allergy mometasone furoate nasal spray for the treatment of allergy symptoms, the first branded Rx-to-OTC switch for Perrigo, and the company expects to launch Nasonex 24HR Allergy sometime in 2022. In 2018, the company announced that it had acquired US rights to an OTC version of Nasonex from Merck. … [Read more...] about FDA approves Rx-to-OTC switch for Perrigo’s Nasonex 24HR Allergy nasal spray
OINDP experts will once again meet in person at RDD 2022
RDD 2022 (May 1-5 in Orlando, Florida) will be the first major OINDP meeting to take place primarily in person since the beginning of the COVID-19 pandemic. According to Richard Dalby of RDD Online, organizers of the Respiratory Drug Delivery conferences, attendees at RDD 2022 in Orlando will find all of the features of RDD meetings they are accustomed to, including … [Read more...] about OINDP experts will once again meet in person at RDD 2022
TFF partners with US army on intranasal dry powder vaccine against SARS-CoV-2
TFF Pharmaceuticals said that the company has entered into an additional Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation for formulation of an intranasal dry powder recombinant vesicular stomatitis virus (rVSV) against SARS-CoV-2 using … [Read more...] about TFF partners with US army on intranasal dry powder vaccine against SARS-CoV-2